CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Tongjitang Chinese Medicines Co. (ADR) is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Tongjitang Chinese Medicines Co. (ADR)
5th Floor, Block B
Nanshan Medical Device Park
Phone: +86 75526891550p:+86 75526891550 Shekou, SHZ  518067  China Ticker: TCM TCM
This company was Merged or Acquired on 9/18/2013.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Tongjitang Chinese Medicines Company (Tongjitang) is a specialty pharmaceutical company focusing on the development, manufacturing and marketing of modernized traditional Chinese medicines. The Company’s product portfolio consists primarily of Xianling Gubao and two other SFDA-approved modernized traditional Chinese medicines designed to address large market opportunities. Tongjitang’s product development pipeline includes expanded uses of its products for additional medical indications and a number of new product candidates that are focused to address medical needs in China, primarily in the therapeutic areas of women’s health, mental health and dermatology. In addition to Xianling Gubao, it manufactures and markets a portfolio of 36 other modernized traditional Chinese medicines approved by the State Food and Drug Administration (SFDA), including two products: Zaoren Anshen Capsules and Moisturizing and Anti-Itching Capsules. In April 2011, it acquired Hanmax Investment Limited.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/201012/31/2009YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
2833 Medicinal chemicals and botanical products

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Executive Officer XiaochunWang 42
Chief Operating Officer, Director YanChen 44 11/1/2006 5/16/2006
Chief Technology Officer LingQin 50 7/1/2006 7/1/2006
3 additional Officers and Directors records available in full report.

Business Names
Business Name
2. Unisources Enterprises Limited
3. Guizhou Tongjitang Pharmaceutical Co., Ltd.
4. Guizhou Long-Life Pharmaceutical Company Limited.
7 additional Business Names available in full report.

General Information
Number of Employees: 2,440 (As of 12/31/2009)
Outstanding Shares: 104,066,526 (As of 6/30/2010)
Stock Exchange: NYSE
Fax Number: +86 75526891529


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023